Details

Written by: JK Monitor News Network

Published: 20 June 2024

• The UNICEF order for ceftriaxone supply is an endorsement of Venus Remedies’ exceptional quality standards and its position as a trusted partner in global healthcare supply chains
• The company also secures a mandate from the world's oldest international public health agency for supplying essential cancer drugs to multiple Latin American countries, fortifying its position as a quality-driven pharmaceutical leader committed to improving global health outcomes
• In line with its mission to enhance global access to quality healthcare, these prestigious orders will also continue to strengthen the company’s international presence.

CHANDIGARH: Three months after getting the coveted Good Manufacturing Practices (GMP) approval from the United Nations International Children's Emergency Fund (UNICEF), leading global pharmaceutical company Venus Remedies Limited has been awarded a tender by UNICEF for supplying ceftriaxone (1gm), a beta-lactam antibiotic, in dry powder form.

Ceftriaxone dry powder is an important drug in Venus Remedies’ extensive antibiotic portfolio. Moreover, ceftriaxone is an important antibiotic globally due to its broad-spectrum activity and effectiveness in treating a variety of serious bacterial infections. The global ceftriaxone market was valued at USD 1.7 billion in 2021 and is expected to grow at a CAGR of 2.9% from 2022 to 2031 to reach over USD 2.2 billion by the end of 2031.

In another development crucial to improving healthcare outcomes in Latin America, Venus Remedies Ltd has also been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world's oldest international public health agency. The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate and vincristine.

Strengthening the company’s position as a trusted partner in the global healthcare supply chains, the company’s collaboration with UNICEF and its inceptive agreement with the PAHO tender authority, signify a notable milestone for Venus Remedies, enhancing its contribution to global health initiatives and reinforcing its commitment to improving global health outcomes by providing life-saving medicines to those who need them the most.

Lauding the achievement as a dual opportunity for the company to extend its reach and serve the needy, Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, “Our association with the PAHO is a monumental step in our mission to deliver high-quality, innovative oncology products to those in dire need. Further, securing the tender with UNICEF reflects our relentless pursuit of excellence and our commitment to improving health outcomes worldwide. Building on such prestigious orders, we will also continue to strengthen our international presence.”

Having exported pharmaceuticals worth about US $16 billion in the financial year 2023-2024, India is the world’s largest provider of generic drugs. In terms of volumes, Indian drugs comprised 20 percent of the global generic drug exports . Venus Remedies is playing a key role in this export market, contributing to India's growing influence, particularly in the global oncology sector.

Ms. Aditi K. Chaudhary, President, International Business, Venus Remedies, said these tenders are a significant endorsement of the company’s vision to provide accessible, high-quality healthcare solutions. “This much-coveted endorsement from UNICEF is a significant prospect for Venus' mission of contributing towards global health. Moreover, association with PAHO reinforces our position as an important player in the global oncology market and underscores our commitment to catering to the Latin American region, which is facing critical challenges in cancer care,” she said.

With over 25 international GMP approvals and 800+ marketing authorizations worldwide, Venus Remedies is rapidly emerging as a frontrunner in the pharmaceutical industry. Having a presence in 90+ countries, the company is poised to become a global leader in the pharma space. 

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001, and OHSAS. The company has also been approved by European-GMP, WHO-GMP, and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.